Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
25 mars 2022 08h00 HE
|
Timber Pharmaceuticals
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE, NJ, March 25, 2022 (GLOBE NEWSWIRE) -- via...
Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
03 févr. 2022 08h00 HE
|
Timber Pharmaceuticals
- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to initiate Phase 3 study in second quarter of 2022 - BASKING RIDGE, NJ, Feb....
Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference
06 janv. 2022 08h00 HE
|
Timber Pharmaceuticals
Virtual Conference on January 10-13, 2022 BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR),...
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001
17 nov. 2021 16h18 HE
|
Timber Pharmaceuticals
Call to be held on Monday, November 22nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results
15 nov. 2021 16h15 HE
|
Timber Pharmaceuticals
Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) --...
Timber Pharmaceuticals Announces Closing of Exercise of Underwriter’s Option to Purchase Additional Common Stock
09 nov. 2021 16h05 HE
|
Timber Pharmaceuticals
Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or...
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
05 nov. 2021 16h05 HE
|
Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering
03 nov. 2021 08h00 HE
|
Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Proposed Public Offering
02 nov. 2021 16h31 HE
|
Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
07 oct. 2021 09h11 HE
|
Timber Pharmaceuticals
Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the...